纽约, 2025年10月31日 - (亚太商讯 via SeaPRwire.com) - TruMerit 公司总裁兼首席执行官彼得·普雷佐西（Peter Preziosi）当选为联合国咨商地位非政府组织会议（简称 CoNGO）主席。CoNGO | TruMerit联合国咨商地位非政府组织会议，亦称为 CoNGO，与 TruMeritCoNGO 是一个成立于 1948 年的国际非政府组织，其与联合国的关系基于联合国经济及社会理事会（ECOSOC）授予的“全面咨商地位”（General Consultative Status）。该组织目前拥有来自世界各地的 525 个会员组织以及 106 个准会员。普雷佐西博士（Dr. Preziosi）于本周在第 28 届 CoNGO 大会上当选为 2025—2029 任期主席。大会在纽约举行，同时也有来自全球各地的组织以线上方式参会。他接替了自 2017 年起担任 CoNGO 主席、并曾在 2007 至 2011 年间任职的联合卫理公会总会社会与公共事务委员会驻联合国首席代表利贝拉托·C·包蒂斯塔牧师博士（Rev. Dr. Liberato C. Bautista）。TruMerit 自 2018 年起成为 CoNGO 成员，并积极参与该组织事务，曾担任 CoNGO 理事会秘书以及会员委员会主席。普雷佐西博士（Dr. Preziosi）是首位担任 CoNGO 主席的注册护士。他是一位非营利机构高管，自 2023 年初起领导 TruMerit（前称 CGFNS International），这是一家致力于促进全球卫生工作者伦理流动与职业发展的卫生人力资源发展组织。此前，他曾就职于世界卫生组织（WHO），协助建立该机构的技术驱动型全球学习中心——世卫学院（WHO Academy）。前任主席包蒂斯塔牧师博士（Dr. Bautista）对普雷佐西博士的当选表示热烈祝贺。他说：“普雷佐西博士在 TruMerit 与世卫组织的工作经验，加上他对多边主义的深切奉献以及他在公民社会中的积极参与，为我们对 CoNGO 的未来带来了信心。在这个公民社会的声音与影响力对于塑造以人类尊严、人权及地球可持续性为核心的共同未来至关重要的时代，普雷佐西博士的领导力有望进一步强化 CoNGO 在联合国体系内外，推动民主与公平参与的重要作用。”普雷佐西表示：“长期以来，CoNGO 一直是非政府组织的重要汇聚平台，是连接公民社会与联合国之间的桥梁，也是包容性多边主义的坚定倡导者——这一理念遗憾地正日益受到冲击。”他进一步指出：“对此，我们应当坚持认为公民社会在联合国的参与不是一种请求，而是一项原则——这一原则对确保多边主义的合法性、有效性和伦理性至关重要，也因此对于实现可持续发展目标以及维护法治具有关键意义。”关于 CoNGO（联合国咨商地位非政府组织会议）联合国咨商地位非政府组织会议（Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations，简称 CoNGO）是一个独立的国际会员协会，成立于 1948 年——《世界人权宣言》发表的同一年。作为具有联合国经济及社会理事会（ECOSOC）全面咨商地位的非政府组织（NGO），CoNGO 的工作涉及整个联合国体系，包括秘书处、各专门机构、条约机构、区域委员会、研究所、峰会及世界会议。CoNGO 全心全意支持《联合国宪章》中所载的目标与价值观，并积极倡导通过多边主义来应对全球政治、环境、卫生及其他挑战。近 30 个隶属于 CoNGO 的实质委员会（即 NGO 委员会）在纽约、日内瓦、维也纳及世界各地区运作，体现了 CoNGO 对联合国体系使命的坚定支持。CoNGO 的成员涵盖广泛领域的非政府组织，这些组织不仅与联合国保持咨商关系，也彼此合作，并与志同道合的利益相关方携手共进。官方网站：ngocongo.org关于 TruMeritTruMerit 是全球领先的医疗人力发展机构。前身为 CGFNS International，该组织拥有近 50 年历史，致力于协助护理人员与其他医疗工作者——以及负责发照与聘用的机构——在寻求在美国及其他国家执业许可时，验证其教育背景、专业技能与实践经验，促进其职业流动性。作为 TruMerit，该机构的使命已扩展为建立符合全球快速变迁健康需求的人力资源能力。通过旗下的全球健康人力发展研究院（Global Health Workforce Development Institute），TruMerit 正在推动以实证为基础的研究、思想领导与倡议，支持各项医疗人力发展方案，包括全球认可的执业标准与认证，藉此强化医疗工作者的职业发展途径。联系信息David St. Johndstjohn@trumerit.org来源: TruMerit Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- Expansive 20,000 square feet centre featuring nearly 300 workstations in the prestigious One IFC.- Luxurious VIP Lounge and designer Members’ Lounge complemented by a fully serviced Barista Bar.- TEC's 13th centre in Hong Kong, reinforcing its leadership in premium flexible workspace solutions.HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – The Executive Centre (TEC), a premium flexible workspace provider, is proud to announce the grand opening of its latest centre at Level 9, One IFC, an iconic address in the heart of Central Hong Kong. This new centre spans nearly 20,000 square feet and accommodates close to 300 workstations, marking a significant milestone as TEC’s 13th centre in the city.This new location epitomizes exclusivity and sophistication, offering a range of high-end amenities tailored to meet the diverse needs of modern professionals. Among its offerings are premium Private Offices, Manager Suites, and an exclusive luxury VIP Lounge designed for high-level meetings, complemented by two additional Meeting Rooms equipped with cutting-edge technology to facilitate seamless collaboration.Jennifer So, City Head of Hong Kong at The Executive Centre, remarked on the importance of this launch: “Since our inception in Hong Kong in 1994, we have strived to set the standard for premium flexible workspaces across Asia. Today, as we celebrate the opening of our new centre at One IFC during our 31st anniversary, we reaffirm our unwavering commitment to excellence. This centre is not merely a new location; it embodies our belief that a harmonious blend of luxury and flexibility is essential for providing our clients with a competitive edge in an ever-evolving business landscape. Our expansion here reflects our confidence in the Hong Kong market and our commitment to supporting businesses in this vibrant city.”The centre features a meticulously designed Members’ Lounge that boasts breathtaking panoramic views of Victoria Harbour, along with a fully serviced Barista Bar. The interior design, characterized by curve-inspired ceilings, a contemporary marble reception, and warm wooden accents, creates an inviting and inspiring atmosphere for all members.Additional highlights include:- A luxurious VIP Lounge that exudes a sense of ‘quiet luxury’ with designer furnishings and exquisite finishes.- Two contemporary Meeting Rooms equipped with cutting-edge technology and exceptional soundproofing for privacy and focus.- Over 2,000 square feet of elegantly appointed Event Space, ideal for hosting corporate events and networking functions.- A thoughtfully designed nursing room featuring a massage chair, catering to the needs of working parents.The Executive Centre at One IFC stands as a testament to TEC’s dedication to delivering best-in-class service and innovative workspace solutions, ensuring that members have access to an environment that fosters productivity and creativity.As TEC continues to expand its footprint in Hong Kong, the opening of this new centre at One IFC reinforces its position as a pioneer in the flexible workspace sector, committed to enhancing the professional experience for all its members.About The Executive CentreThe Executive Centre (TEC) is a premium flexible workspace provider, opened its doors in Hong Kong in 1994 and has over 240+ Centres in 37 cities and 15 markets.The Executive Centre caters to professionals and industry leaders. TEC has a global network spanning Greater China, Southeast Asia, North Asia, India, Sri Lanka, the Middle East, and Australia. Each Executive Centre offers a prestigious address with the advanced infrastructure to meet the needs of its Members.Privately owned and headquartered in Hong Kong, TEC provides Private and Shared Workspaces, Business Services, and Meeting & Events facilities to suit its clients’ business' needs.www.executivecentre.comPress EnquiriesThe Executive CentrePebble LeePebble_lee@executivecentre.com / +852 3951 9888 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - October 30, 2025) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (the "Company" or "Doubleview") is pleased to announce a non-brokered private placement of flow-through shares and non-flow-through units for gross proceeds of up to C$10,000,000 (the "Private Placement"). Proceeds of the Private Placement shall be used to fund the current exploration program and general working capital. Proceeds of the sale of the FT Shares will be used for exploration work on its BC projects, particularly for the polymetallic Hat Project, located in northwestern BC. This work includes drilling, geological advisory and analytical services as well as other development work and other "Canadian exploration expenses" that qualify as "flow-through mining expenditures" (as such terms are defined in the Income Tax Act (Canada) (the "Tax Act")).The flow-through portion of the Private Placement will consist of up to 5,000,000 flow-through Shares ("FT shares ") at a price of $1.00 per FT share for up to C$5,000,000.Additionally, the Company will issue up to 7,142,857 hard dollar units ("non-FT Units") at a price of $0.70 per non-FT Unit, for up to C$5,000,000. Each non-FT Unit will consist of one common share and one full Warrant at an exercise price of $1.00 for 24 months from the date of issue. Each Warrant shall be subject to an accelerated expiry date at the option of the Company in the event the ten (10) day volume-weighted average price of the common shares of the Company on the TSXV for any ten (10) consecutive trading days is $1.25 or more.Pursuant to applicable Canadian securities laws and in accordance with the TSX Venture Exchange policies, all securities issued under this Offering will be subject to applicable resale restrictions under applicable securities laws and to the Exchange hold period of four-months and one day from the date of issuance. In connection with the Private placement, Doubleview may pay a finder's fees in accordance with the policies of the TSXV consisting of cash and/or finder's shares.The closing of the Offering is subject to receipt of all necessary regulatory approvals including the TSX Venture ExchangeAbout Doubleview Gold CorpA mineral resource exploration and development company is headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX Venture Exchange (TSXV: DBG) (OTCQB: DBLVF) (WKN: A1W038) and (FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals-utilizing cutting-edge exploration techniques.Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.About the Hat Polymetallic DepositThe Hat Deposit, located in northwestern British Columbia, is a polymetallic porphyry project with major resources of copper, gold, cobalt, and the potential for scandium. As one of the region's significant sources of critical minerals, the Hat deposit has undergone targeted exploration and development. The 0.2% CuEq cut-off resource estimate, as of the recently completed Mineral Resource Estimate and the Company's July 25, 2024, news release, is summarized below:Open Pit Model HatResource CategoryTonnageAverage GradeMetal ContentCuEqCuCoAuAgCuEqCuCoAuAgMt%%%g/tg/tmillion lbmillion lbmillion lbthousand ozthousand ozIn PitIndicated1500.4080.2210.0080.190.421,353733289292,045Inferred4770.3440.1850.0090.150.493,6191,945912,3287,575 Scandium potential for the Hat Deposit is estimated to be 300 to 500 million tonnes at an average grade of 40 ppm (0.004%) Sc2O3.For further details, please refer to the Company's July 25, 2024 news release.Qualified Person:Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview's Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the written technical disclosure contained in the news release. He is not independent of Doubleview as he is a shareholder in the company.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BC Farshad ShirvaniPresident & CEOT: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.The information contained herein contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively, "forward-looking statements"). Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. All statements, other than statements of historical fact, are forward-looking statements and are based on predictions, expectations, beliefs, plans, projections, objectives and assumptions made as of the date of this news release, including without limitation: the size of the Private Placement and other statements concerning the Private Placement; the anticipated use of proceeds from the Private Placement; the renunciation to the purchasers of FT Shares and timing thereof; the tax treatment of the FT Shares and the Company's plans regarding exploring its mineral exploration properties; anticipated results of geophysical drilling programs, geological interpretations and potential mineral recovery. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate funding on a timely basis and on acceptable terms; risks related to the outcome of legal proceedings; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings; risks related to environmental regulation and liability; the potential for delays in exploration or development activities or the completion of feasibility studies; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; results of prefeasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to the gold price and other commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in the Company's disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty or reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise any forward-looking statements, other than as required by applicable law, to reflect new information, events or circumstances, or changes in management's estimates, projections or opinions. Actual events or results could differ materially from those anticipated in the forward-looking statements or from the Company's expectations or projections.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272690 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月31日 - (亚太商訊) - 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能创新疗法，以解决代谢性慢病未满足临床需求的创新药公司，宣布HTD1801在2型糖尿病（T2DM）患者中开展的两项III期临床试验（SYMPHONY-1和SYMPHONY-2）已顺利完成。在包含双盲治疗期和开放延长治疗期（OLE）的52周研究中，HTD1801展现出长期持久的疗效与良好的安全性。两项III期临床研究的52周数据充分验证了HTD1801疗效的持久性，并进一步凸显其为T2DM患者带来的长期综合临床获益。君圣泰医药计划于今年内向国家药品监督管理局（NMPA）药品审评中心（CDE）递交HTD1801治疗T2DM适应症的新药上市申请（NDA）。SYMPHONY-1（NCT06350890）及SYMPHONY-2（NCT06353347）试验是两项随机、双盲、安慰剂对照的III期临床试验，旨在分别评估HTD1801在饮食及运动干预后血糖控制不佳（SYMPHONY-1; N=408）和二甲双胍治疗后血糖控制不佳（SYMPHONY-2; N=551）的T2DM成人受试者中的有效性和安全性。两项研究的主要疗效终点为：与安慰剂相比，HTD1801治疗24周后糖化血红蛋白（HbA1c）相对于基线的变化。随后所有受试者进入为期28周的OLE期并接受HTD1801的治疗。研究继续评估了各疗效终点在第52周时相对于基线变化，以进一步验证HTD1801疗效的持久性。降糖疗效稳健持久：24 周双盲期疗效得到长期维持，52 周数据印证 HTD1801 带来持久获益SYMPHONY-1（单药治疗）：HTD1801治疗组第24周HbA1c较基线平均变化值为-1.3%，显著优于安慰剂组。持续接受HTD1801治疗的患者在第52周时HbA1c的较基线降幅（-1.2%）维持稳定。由安慰剂转至HTD1801治疗的患者，在第52周时其HbA1c较基线的平均变化值为-1.3%，进一步验证了双盲期结果的可靠性。SYMPHONY-2（与二甲双胍联合治疗）：HTD1801治疗组第24周HbA1c较基线平均变化值为-1.2%，显著优于安慰剂组。持续接受HTD1801治疗的患者在第52周时HbA1c的较基线降幅（-1.1%）依然稳定。由安慰剂转换至 HTD1801治疗的患者，在第52周时其 HbA1c较基线的平均变化值为-1.2%，再次印证了双盲期的研究结果。心肾代谢多重获益：HTD1801 对多项心肾代谢指标的改善在 52 周时均持续获益两项研究中，双盲期HbA1c达标（HbA1c <7.0%）的患者比例在第 52 周时仍保持稳定。与此同时，HTD1801 在降低血脂方面的疗效亦长期稳定，包括低密度脂蛋白胆固醇（LDL-C）与非高密度脂蛋白胆固醇（non-HDL-C）均显著下降。HTD1801长期治疗还可持续降低与心血管事件及T2DM患者临床结局密切相关的炎症标记物γ-谷氨酰转移酶（GGT）和超敏C反应蛋白（hs-CRP）。值得关注的是，全体患者的估算肾小球滤过率（eGFR）在治疗期间保持稳定。在合并轻度肾功能损害的患者中，第 24 周观察到的 eGFR 改善在第 52 周时仍然保持，显示HTD1801的肾脏保护潜力。相关数据将在近期学术会议公布。良好的安全性与耐受性HTD1801 在长期治疗中展现出良好的安全性与耐受性，与双盲期结果保持一致。对于接受 HTD1801 治疗的患者，治疗期延长不会增加其不良事件的类型与严重程度。该临床试验的主要研究者，前国际糖尿病联盟（IDF）副主席、北京大学糖尿病中心主任、北京大学人民医院内分泌和代谢科主任纪立农教授指出：“这两项临床试验52 周研究结果进一步表明，HTD1801有望成为T2DM患者差异化的创新治疗选择。HTD1801是全球首创的新分子实体，作为抗炎代谢调节剂（AIMM），具有激活AMPK并抑制 NLRP3 炎性小体的双重作用机制，与现有治疗方案在机制上有很大的差异。其独特药理机制在临床疗效上表现出多重获益：不仅能够有效降糖，还可改善脂质代谢，抑制慢性代谢性炎症，并有改善肾功能的潜力。这一综合疗效使 HTD1801 有潜力成为心肾代谢系统疾病（CKM）的新治疗药物，有改善糖尿病及相关并发症的关键驱动因素的潜力，并和现有降糖药物机制互补，能够联合使用。”君圣泰医药的创始人、董事长兼首席执行官刘利平博士表示：“我们向参与这几项关键临床研究的患者致以诚挚的谢意。对于T2DM 这类慢性进展性疾病而言，疗效的持久性是衡量长期治疗成功的核心标准。HTD1801在代谢、炎症及肾功能等多个层面展现出的持久获益，有助于降低微血管及大血管并发症的风险。我们期待即将公布的与达格列净头对头的III期研究结果，并将继续挖掘 HTD1801 其它适应症的临床潜力，为慢性代谢性疾病患者提供更综合全面、且长期有效的治疗方案。”关于2型糖尿病（T2DM）根据国际糖尿病联盟（IDF）统计，2024年有5.89亿成年人（20-79岁）患有糖尿病，预计到2050年将增至8.53亿（即每8个成年人中就有1人患有糖尿病），其中90%为T2DM。中国是全球糖尿病患者人数最多的国家，2024年患者人数约为1.48亿人，预计2050年将增至1.68亿人。目前，糖尿病每年导致超过600万人死亡，该疾病及其相关的一系列代谢问题，给社会和人民带来了沉重的负担。为应对这一急迫挑战，临床上急需为全球患者带来综合获益的创新疗法。关于HTD1801HTD1801是一款全球首创的新分子实体，旨在解决心肾代谢系统疾病（CKM）的未满足临床需求。HTD1801是口服抗炎及代谢调节剂（AIMM），作为单一分子具有独特双机制 ，通过激活AMPK及抑制NLRP3炎症小体发挥其生物学活性；这种互补协同的双机制作用可有效缓解代谢问题。全球多项临床结果验证HTD1801具有“一药多效”的特性，能够为患者带来综合获益，包括改善胰岛素敏感性、血糖控制、血脂降低、肾脏保护、体重减轻、肝脏获益及抗炎等。基于此，HTD1801有潜力成为CKM领域的基础性治疗药物。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).The 52-week data from these two Phase III clinical trials demonstrate the durability of response and highlight the comprehensive long-term clinical benefits of HTD1801 in patients with T2DM. HighTide plans to submit a new drug application (NDA) for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) later this year.SYMPHONY-1 (NCT06350890) and SYMPHONY-2 (NCT06353347) are randomized, double-blind, placebo-controlled, Phase III clinical trials designed to evaluate the efficacy and safety of HTD1801 in adults with T2DM and inadequate glycemic control despite diet and exercise (SYMPHONY-1; N=408) or with Metformin (SYMPHONY-2; N=551). The primary endpoint in both studies was the change in glycated hemoglobin (HbA1c) from baseline with HTD1801 compared to placebo after 24 weeks of treatment. Patients were eligible to continue in a 28-week OLE during which all patients received HTD1801; Durability of response across efficacy endpoints was evaluated based on the change from baseline to Week 52.Efficacy observed during the 24-week double-blind period was durable and maintained with longer-term treatment through 52 weeks in both studiesSYMPHONY-1 (HTD1801 as monotherapy): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.3%) was superior to placebo. HbA1c reductions were maintained in patients who continued receiving HTD1801 (-1.2% at Week 52). Placebo patients who switched to HTD1801 saw a reduction in HbA1c of -1.3% at Week 52, substantiating the double-blind phase findings.SYMPHONY-2 (HTD1801 as an add-on therapy to Metformin): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.2%) was superior to placebo. HbA1c reductions were sustained in patients who continued receiving HTD1801 (-1.1% at Week 52). Placebo patients who switched to HTD1801 saw a reduction in HbA1c of -1.2% at Week 52, also substantiating the double-blind phase findings.In both studies, the durability of effect on other cardiometabolic and renal endpoints was maintained at 52 weeks, suggesting comprehensive advantages of HTD1801 beyond glycemic control with long-term treatment.In both studies, the proportion of patients receiving HTD1801 during the double-blind phase who achieved target HbA1c<7.0% was sustained through Week 52. The lipid-lowering effects observed during the double-blind phase, including significant reductions in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C), were also maintained. Long-term HTD1801 treatment also led to continued reductions in key inflammatory biomarkers, including gamma-glutamyl transferase (GGT) and high-sensitivity C-reactive protein (hs-CRP), both associated with cardiovascular risk in patients with T2DM.Notably, while estimated glomerular filtration rate (eGFR) remained stable in the overall population, the improvement of eGFR in patients with mild renal impairment at Week 24 was preserved at Week 52. These data highlighting the potential renal benefit of HTD1801 will be presented at a forthcoming scientific meeting.Favorable safety and tolerability profileOverall, long-term safety and tolerability were favorable and consistent with the double-blind phase. The types and severity of AEs did not increase with continued HTD1801 treatment compared to newly initiated HTD1801 treatment.“The robust 52-week results from these trials reinforce that HTD1801 may represent a novel and truly differentiated therapeutic option for patients with T2DM,” said Dr. Linong Ji, Lead Principal Investigator, former Vice President of the International Diabetes Federation (IDF), and Director of the Peking University Diabetes Center and the Department of Endocrinology and Metabolism at Peking University People’s Hospital. “As a first-in-class new molecular entity, HTD1801 is an anti-inflammatory metabolic modulator (AIMM) with a dual mechanism of action, AMP kinase activation and NLRP3 inflammasome inhibition, distinct from existing therapies. Its unique profile is designed not only to lower blood glucose, but also to improve lipid metabolism, exert anti-inflammatory effects, and potentially enhance renal function, supporting its potential as a backbone therapy to address the cardiovascular-kidney-metabolic (CKM) syndrome by targeting the underlying drivers of diabetes and diabetes-related complications. In addition, the unique mechanism allows for potential of combination treatments”“We extend our deepest gratitude to the patients who participated in these pivotal studies,” said Dr. Liping Liu, Founder, Chairperson, and CEO of HighTide Therapeutics. “Given the progressive nature of T2DM, durability of effect is a key determinant of long-term therapeutic success. The sustained beneficial effects of HTD1801 on metabolic, inflammatory, and renal parameters help reduce the risk of both microvascular and macrovascular complications. We look forward to sharing results from our Phase III head-to-head study with dapagliflozin, and will continue to explore HTD1801’s potential to deliver patients with chronic metabolic diseases a truly comprehensive, long-term treatment solution.”About Type 2 Diabetes Mellitus (T2DM)According to the International Diabetes Federation (IDF), 589 million adults (ages 20-79) were living with diabetes in 2024, and this number is projected to grow to 853 million (representing 1 in 8 adults) by 2050, of these, around 90% are T2DM cases. China has the largest population of diabetes patients worldwide, estimated to be 148 million in 2024, and projected to grow to 168 million in 2050. Diabetes is a global societal burden leading to over 6 million deaths per year. To address this urgent challenge, there is a critical need for innovative therapies that can deliver comprehensive clinical benefits for patients worldwide.About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundation therapy in CKM disease management. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit President and CEO Peter Preziosi has been elected President of the Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO.CoNGO | TruMeritConference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO and TruMeritCoNGO is an international non-governmental organization founded in 1948 that relates to the United Nations through its General Consultative Status granted by the United Nations Economic and Social Council (ECOSOC). It has 525 member organizations from around the world and 106 associate members.Dr. Preziosi was elected to serve for the 2025-29 term this week at the 28th CoNGO General Assembly, which took place in New York with the virtual participation of organizations from around the world. He succeeds the Rev. Dr. Liberato C. Bautista, the main representative to the UN for the General Board of Church and Society of The United Methodist Church, who has served as CoNGO's President since 2017 and also held the post from 2007 to 2011.TruMerit has been a member of CoNGO since 2018 and is active in the organization's affairs, having served as the organization's Secretary to the CoNGO Board and as chair of its Membership Committee.Dr. Preziosi is the first Registered Nurse to serve as CoNGO President. He is a nonprofit executive who since early 2023 has led TruMerit, formerly known as CGFNS International, a health workforce development organization committed to advancing the ethical mobility and professional growth of health workers worldwide. Previously, he was employed by the World Health Organization to help establish its technology-driven global learning center, the WHO Academy.Dr. Bautista, the former President of CoNGO, extended his warm congratulations to Dr. Preziosi on his election. "His experience at TruMerit and at WHO, coupled with his profound dedication to multilateralism and his engagement with civil society, provide a basis for optimism regarding CoNGO's future. In an era where the voice and influence of civil society are of paramount importance in shaping a shared future that upholds human dignity and rights, as well as planetary sustainability, Dr. Preziosi's leadership is expected to enhance CoNGO's role as a pivotal supporter and advocate for democratic and equitable participation within the United Nations and beyond," he stated."CoNGO has long been a vital convener of NGOs, a bridge between civil society and an advocate for their engagement at the United Nations, as well as a steadfast champion of inclusive multilateralism - a concept that, unfortunately, is increasingly under attack," said Preziosi."In response, let us assert civil society participation at the United Nations not as a plea, but as a principle - one that is essential to legitimate, effective, and ethical multilateralism, and thereby is critical to the attainment of the Sustainable Development Goals and adherence to the rule of law," he said.About CoNGO (Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations)The Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations (CoNGO) is an independent, international membership association founded in 1948, the year of the Universal Declaration of Human Rights. As a non-governmental organization (NGO) in general consultative status with the UN Economic and Social Council, our work relates to the entire United Nations System: the Secretariat, Agencies, Treaty Bodies, Regional Commissions, Institutes, Summits and World Conferences.CoNGO wholeheartedly endorses the goals and values enshrined in the United Nations Charter and is a strong advocate for multilateralism to resolve global political, environmental, health, and other threats. Close to 30 CoNGO Substantive Committees (called NGO Committees) related to CoNGO in New York, Geneva, Vienna, and regions worldwide demonstrate our commitment to supporting the mission of the United Nations, systemwide. CoNGO has a membership of diverse NGOs working in consultation with the United Nations, in collaboration with each other, and in cooperation with other like-minded stakeholders. ngocongo.orgAbout TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers - and those who license and hire them - by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers. www.trumerit.orgContact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Auckland, New Zealand, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - At the inaugural European Union – New Zealand Business Summit, Decent Cybersecurity represented Europe's growing strength in digital and defence technologies. The company's Founder and CEO, Matej Michalko, joined industry leaders to discuss innovation partnerships, cybersecurity resilience, and post-quantum readiness across trans-Pacific markets. The event gathered over 400 participants from business, technology, and research communities, underscoring a shared commitment to building secure and sustainable digital infrastructure between Europe and New Zealand.Hosted by Hon Todd McClay, New Zealand's Minister for Trade & Investment, in partnership with Team Europe (the Ambassadors of the EU and its Member States), the Summit celebrated the strong growth of trans-Pacific cooperation. Since the EU–NZ Free Trade Agreement entered into force in 2024, two-way trade has already risen by NZ $2 billion, reaching NZ $21.6 billion in 2025.The event was officially opened by Prime Minister Christopher Luxon, who described the EU as "an innovation partner" and emphasised the shared values and strategic alignment between Europe and New Zealand in advancing trade, defence, and technology.A Platform for Global Partnerships and Digital InnovationCommissioner Šefcovic, a native of Slovakia, delivered a keynote address outlining Europe's vision for resilient supply chains, strategic autonomy, and secure digital transition. Later in the day, the "Quickfire with Central and Eastern Europe" session showcased innovation leaders from across the region.Representing European Union and its member country Slovakia, Matej Michalko presented on the country's growing role in post-quantum cybersecurity, AI for defence systems, and trusted blockchain infrastructure — areas where Decent Cybersecurity is establishing Europe-wide leadership."It was an honour to represent European Union and Slovakia alongside Commissioner Šefcovic and to demonstrate how our country is contributing to Europe's digital and defence sovereignty," said Matej Michalko, CEO of Decent Cybersecurity. "The EU–New Zealand partnership opens new doors for innovation, technology exchange, and secure infrastructure development that transcend continents."Shared Vision for Innovation and SecurityThe Summit agenda featured strategic panels on clean tech, AI, bioeconomy, and aerospace & defence, with global leaders from Airbus, Rocket Lab, OHB, and Maersk. It culminated with a joint address by Commissioner Šefcovic and Minister McClay, setting out a shared vision for deeper economic and technological integration between Europe and New Zealand — an effort strongly endorsed by Prime Minister Luxon in his opening remarks.For Decent Cybersecurity, participation in this summit reinforces its mission to connect European post-quantum, blockchain and AI-driven innovation with global partners in the Asia-Pacific region — bridging defence, technology, and critical-infrastructure ecosystems.About Decent CybersecurityDecent Cybersecurity s. r. o. is a European deep-tech company developing post-quantum and blockchain-based cybersecurity solutions for defence and critical infrastructure. Certified by TÜV SÜD (ISO 9001 and ISO 27001) and holding NATO, EU, and national SECRET-level security clearances, the company is a member of European Defence Fund (EDF) projects and a founding member of the Critical Infrastructure Association of Slovak Republic (Asociácia kritickej infraštruktúry SR, AKI SR).Media contactBrand: Decent CybersecurityContact: Media teamWebsite: https://decentcybersecurity.eu Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world's first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC).MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10.The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China.If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon's ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon's product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector.On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.About AD IndicationMG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group.Reference:1. China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry2. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Esperanza Fintech (Hong Kong) Limited (“Esperanza” or the “Group”) today hosted the “Conference: Implementation of Tokenized Economy by Esperanza” (“Conference”). It is an opportune moment as the Hong Kong SAR Government vows in her 2025 Policy Address to support the development of tokenized gold investment products. The Conference brought together industry leaders and partners to map out a strategic blueprint to implement tokenized economy, including the compliant roadmap for tokenized gold in Hong Kong and the unlimited potential of tokenized investments, an application for tokenized gold, in driving economic growth in the Asia-Pacific region. The Conference was attended by nearly a hundred investors and professionals.The Conference kicked off with a vision speech delivered by Mr. Ronald Leung, solicitor, Founder and Group CEO of Esperanza. Mr. Leung pointed out that the Asia-Pacific region has long relied on Western settlement systems and Western-dominated interest rate policies. The tokenized economy, powered by tokenized gold, offers an alternative capital solution to drive regional economic development and the continuous internationalization of the financial and capital markets of the Chinese Mainland  and Hong Kong . He emphasized that the support for development of tokenized gold in Hong Kong’s 2025 Policy Address is a highly strategic policy direction. Capitalizing on her status and resources as an international financial center, Hong Kong possesses unparalleled edge in developing an ecosystem powered by tokenized gold in facilitating cross-border trades in the Asia-Pacific region. Furthermore, tokenized gold could be integrated with Central Bank-led digital Renminbi (RMB) in the future to contribute to the internationalization of RMB. He pointed out that the Group has completed registration with the Hong Kong Customs as an issuer of precious asset-backed instrument. The Group has also undergone a small-scale, non-public proof-of-concept (POC) testing in multiple Asia Pacific markets, including Southeast Asia, Australia, Japan, South Korea, and currently has significant verified “Know Your Customer (KYC)” POC users. Although Esperanza's tokenized gold is designed based on the legal framework for precious asset-backed instrument registered with Hong Kong Customs, to ensure overall regulatory stability in Hong Kong, it is anticipated that Esperanza will open its tokenized gold offerings to the Hong Kong public only after addressing the concerns of other regulatory bodies and when a clear regulatory framework is fully implemented in the city. The Group will also align with governments of various economies on operational fronts via strategic partners.Mr. Leung continued to point out, "Tokenized gold is a key milestone for Hong Kong's financial future. Esperanza has already signed an agreement with Hatcher Group Limited (8365.HK) regarding the development of tokenized gold before the Policy Address was released. Immediately following the release, our team has conducted a productive and in-depth communication with the Chief Executive's Policy Unit, while ensuring our technology platform and infrastructure are in place and ready for action. Currently, we are maintaining active dialogues with regulators, with the core principle of achieving ‘controllable innovation’ that adheres to existing regulatory framework as well as the work agenda of the Chief Executive’s Policy Unit. We firmly believe that Esperanza, armed with first-mover advantages in technology and its business model, and in collaboration with various sectors, will be able to transform tokenized gold into a powerful engine in driving economic autonomy in the Asia-Pacific region."The conference had two thematic sharing sessions. The first had Mr. Roy Lui, Managing Director of ESPE Gold Solutions, sharing the compliant implementation of tokenized gold in Hong Kong. Mr. Lui shared that the Group’s proposed solution – “ESPE Gold” (“ESPG”) – is legally categorized as a “precious asset-backed instrument” instead of a virtual asset or a stablecoin, nor a collective investment scheme. Esperanza purchases physical gold bars adhering to London Bullion Market Association (LBMA) standards, stores them in licensed gold vaults and issues 100,000 ESPG, i.e. digital gold certificates, for each kilogram of gold bar. These digital gold certificates, each representing a complete instalment payment, are recorded on blockchain networks. Upon completion of 100,000 instalments, i.e. holding 100,000 ESPG, clients can redeem physical gold bars from Esperanza. Clients can make instalment payments any time and sell ESPG back to Esperanza, enjoying much higher flexibility than traditional gold redemption clubs. Mr. Lui emphasized that, although ESPG gives users experiences similar to that of stablecoins, the business model is actually more akin to traditional gold dealers earning bid-ask spread. He also spoke on the diverse application scenarios of ESPG besides as a convenient way to purchase physical gold. ESPG is poised to develop into a cross-border settlement means for commerce across Asia economies, with future potential to power a gold-backed interest rate system through collateralized lending of ESPG.In the second sharing session, Mr. Tony Chang, Executive Director of ESPE Capital Solutions, talked about the Group’s blueprint for tokenized investments as a core use case for tokenized gold. Mr. Chang said tokenized investments have not seen significant breakthrough due to the lack of product designs that are attractive to investors and that liquidity is highly concentrated within professional investors. Tokenized investments need to deliver both “attractive growth potential” and “security in exit channels” in order for investors to make meaningful consideration for adoption. Such example includes a short-term revenue sharing arrangement with foreseeable potential for revenue improvement. He added that Esperanza has obtained the Asset Management licence from the Securities and Futures Commission (SFC) of Hong Kong and its application for tokenized business is currently under review, with the legal, tax, and trading infrastructures ready. Currently, the Group’s tokenized investment pipelines include concert revenue of Southeast Asian and Korean artists, movie box office receipts and revenue of hotels and shopping malls.In addition to the thematic sharing sessions, the conference also featured a panel discussion comprising Mr. Jeremy Teo from Singapore, Co-founder and Board Director of Esperanza, Mr. Ronald Leung and Mr. Tony Chang. The discussion centers on the development potential of tokenized gold and tokenized investments across various Asia-Pacific economies, particularly the opportunities in bringing Southeast Asian projects to Hong Kong for capital raising via security token offerings (STOs). These opportunities illustrate the advantages for Hong Kong in developing tokenized gold with the support of the Hong Kong SAR Government.The conference marked an important step made by Esperanza in promoting the development of tokenized economy in Hong Kong and across Asia. Looking ahead, the Group will continue to provide innovative fintech solutions to support Hong Kong in strengthening her position as an international financial center, as well as helping foster greater economic autonomy and financial innovation in the Asia-Pacific region.Photo captionsPhoto 1: (From left to right) Mr. Tony Chang, Executive Director of ESPE Capital Solutions, and Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Roy Lui, Managing Director of ESPE Gold Solutions, at the conference.Photo 2: (From left to right) Mr. Jeremy Teo, Co-founder and Board Director of Esperanza, Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Tony Chang, Executive Director of ESPE Capital Solutions, after the panel discussion session.About Esperanza Fintech (Hong Kong) Limited (Esperanza)Esperanza is co-founded by the next generation of professionals from Hong Kong and Singapore with the mission to reform Asia’s economies through fintech. Esperanza is building the world’s first digital economy powered by a compliant tokenized gold infrastructure and its applications in finance. Esperanza aspires to reconnect Asia’s economies and integrate with their respective Central Bank Digital Currencies (CBDCs) to build autonomy against reliance on Western settlement systems and interest rate policies.Esperanza operates on a low-profile, highly efficient, and decisive business model. Since commencement in 2025, Esperanza has secured the registration as a Precious Metals and Stones Dealer (DPMS) with Hong Kong Customers and the Trust or Company Service Provider (TCSP) licence for the operations and custody of tokenized gold, and the Asset Management licence with the Securities and Futures Commission (SFC) of Hong Kong for the development of tokenized investments.In August 2025, Esperanza entered into a partnership agreement with Hatcher Group (8365.HK) relating to tokenized gold and tokenized investments. In September 2025, Hong Kong government has included the development of tokenized gold into its 2025 Policy Address.Esperanza's tokenized gold and tokenized investments continue to adhere to Hong Kong's Anti-Money Laundering (AML) requirements and common reporting standard for counter-tax evasion measures. Fintech solutions have enabled Esperanza to significantly reduce financing and operational costs, connecting products directly with end users. Esperanza’s tokenized finance system will fully support the globalization of national economy and is committed to becoming an alternative solution for international trades and settlements.To find out more, please visit the Esperanza website: espetopia.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2025年10月30日 - (亚太商訊) - 康哲药业控股有限公司（"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业2025年4月22日发布的公告）连同其附属公司拥有共同开发权（除特应性皮炎（AD）外）和独家商业化权利的1类新药抗IL-4Rα MG-K10人源化单抗注射液（"MG-K10"或"产品"）中国上市许可申请（"NDA"）于2025年10月30日获得中国国家药品监督管理局（NMPA）受理。产品拟用于治疗外用药控制不佳或不适用外用药治疗的成人中重度特应性皮炎。MG-K10（通用名为柯美奇拜单抗注射液）是一种创新的长效抗IL-4Rα人源化单抗，能同时阻断关键2型炎症因子IL-4和IL-13的信号传导。凭借更长的半衰期，产品可实现4周一次的给药频率（已上市抗IL-4Rα药物均为2周一次给药频率），提升患者依从性，并有望成为全球首个上市的长效抗IL-4Rα单抗，具有成为同类最优（Best-in-Class）的潜力。MG-K10已在成人中重度AD的一项随机、双盲、安慰剂对照III期临床研究取得阳性结果，达到方案设计的临床试验主要研究终点，且MG-K10治疗52周时，研究者整体评估（IGA）评分达到0或1分，且较基线改善≥2分的受试者比例为 76.6%；达到湿疹面积及严重程度指数评分较基线至少改善75%（EASI 75）的受试者比例为94.3%；达到湿疹面积及严重程度指数评分较基线至少改善90%（EASI 90）的受试者比例为79.1%。安全性方面，治疗期不良事件（TEAE）大多数为1-2级，未发生特别关注不良事件（AESI），未发生导致死亡的不良事件。同靶点药物常见的不良反应（结膜炎、注射部位反应等）MG-K10发生率较低。产品有潜力用于治疗其他2型炎症性疾病，如哮喘、结节性痒疹、季节性过敏性鼻炎、慢性阻塞性肺疾病、慢性自发性荨麻疹、慢性鼻窦炎伴鼻息肉及嗜酸性粒细胞性食管炎等。其中，哮喘、结节性痒疹和季节性过敏性鼻炎均已进入中国III期临床试验阶段。若该产品获批上市，将为超1,450万中重度AD患者[1]带来新的有效且安全的系统治疗选择。同时，MG-K10将与德镁医药的磷酸芦可替尼乳膏（轻中度AD）、口服小分子TYK2抑制剂CMS-D001（中重度AD），及皮肤学级护肤品禾零舒缓系列形成协同效应，构建覆盖注射、口服与外用等多种给药途径，兼顾"治疗+护理"多重需求的AD综合解决方案，惠及广大特应性皮炎患者；并将进一步丰富德镁医药皮肤治疗领域的产品矩阵，巩固其在皮肤健康领域的领先地位。于2025年1月24日，康哲药业通过其附属公司与湖南麦济生物技术股份有限公司及其附属公司就MG-K10签订合作协议（"协议"）。根据该协议及补充约定，康哲药业获得了产品在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及新加坡的共同开发权（除AD外）及独家商业化权利；其中旗下德镁医药通过其附属公司获得该产品在皮肤科适应症领域于中国大陆的共同开发权（除AD外）及独家商业化权利。关于AD适应症MG-K10的首发适应症AD是一种伴有剧烈瘙痒的慢性炎症性皮肤病，是全球疾病负担最高的非致命性皮肤病，同时也是我国患病率较高、疾病负担较重的慢性疾病。据估算，2024年中国特应性皮炎患者超过5,400万人，基于SCORAD评分，中重度特应性皮炎的占比为27%，即超过1,450万患者[1]。由于传统AD系统治疗药物疗效及安全性等方面的不足，在临床中，中重度AD患者启动系统治疗往往较晚、依从性不佳、总体控制率较低，临床上仍存在大量未被满足的治疗需求[2]。MG-K10给药间隔更长，每4周给药一次，有望提升患者依从性，给中重度AD患者带来新的有效且安全的系统治疗选择。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1. 灼识咨询.《全球及中国皮肤科治疗与护理行业研究报告》2. 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 中国中重度特应性皮炎诊疗临床路径专家共识（2023版）[J] . 中华皮肤科杂志, 2023, 56(11) : 1000-1007. DOI: 10.35541/cjd.20230247.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol “NBP”), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries.This collaboration marks Everest’s strategic expansion into ophthalmology, a high-potential “blue-ocean” therapeutic area, further enriching its late-stage product pipeline and strengthening synergies across its core therapeutic portfolio.Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales.“We are pleased to collaborate with Visara. This partnership brings a highly differentiated and commercially attractive asset to Everest’s late-stage product pipeline and marks our entry into ophthalmology, a competitively attractive therapeutic area with significant unmet medical needs,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Leveraging Everest’s clinical development and commercialization expertise, we look forward to advancing VIS-101, a potential best-in-class bifunctional antibody, towards commercialization in China and across Asia.”VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2 that is more potent and could potentially provide more durable treatment benefits than existing treatments for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed initial safety and dose-escalation studies in both the United State of America and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.“VIS-101 is anticipated to be second-in-class with best-in-class potential, based on bioengineered, superior target neutralizing capabilities.” said Dr. Emmett T. Cunningham, Jr, Co-Founder and Executive Chairman of Visara.Globally, the market size for anti-VEGF ophthalmic drugs reached approximately USD 23 billion in 2024 and is projected to exceed USD 40 billion by 2030. In China alone, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment. This indicates vast market potential.Visara is a subsidiary of NovaBridge Biosciences (Nasdaq: NBP), of which Everest Medicines is currently the largest shareholder. “Licensing out Greater China, South Korea and Southeast Asia rights to Everest Medicines is an important step toward streamlining global commercial rights and creating synergy in global clinical development,” said Dr. Sean Fu, Chief Executive Officer of NovaBridge Biosciences. “We are excited to work with Everest Medicines team as a strategic partner."Under its “dual-engine” strategy, Everest Medicines has established a commercialization platform anchored by two blockbuster products targeting high-potential markets and powered by the in-house in vivo CAR-T and mRNA therapeutic cancer vaccine platforms. The Company will continue to focus on key therapeutic areas and new growth markets, with ophthalmology as the next growth driver to strengthen synergy across its core portfolio.Everest’s core product pipeline in rental diseases, infectious diseases, and autoimmune disorders has entered a critical growth stage. NEFECON® and XERAVA® have established sustainable commercial cash flow generation, while VELSIPITY® (etrasimod) is expected to become the company’s next blockbuster product. Everest continues to enhance its innovation capability and long-term competitiveness by leveraging its industry-leading mRNA therapeutic cancer vaccine platform and mRNA in vivo CAR-T platform.At a recent corporate strategy meeting, Everest Medicines announced plans to in-license more than three high-potential assets within the next 6–12 months, with an aggregate domestic peak sales potential exceeding RMB10 billion. Combined with its existing portfolio, Everest Medicines expects its total domestic peak sales potential to surpass RMB20 billion. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 10月30日，云顶新耀宣布已与Visara签订协议，获得独家许可，在大中华区、新加坡、韩国及若干东南亚国家进行临床开发、生产和商业化VIS-101。该合作标志着云顶新耀正式进军眼科这一高潜力蓝海领域，丰富了公司的后期产品管线，进一步拓展其核心治疗领域布局。根据指定独家许可，云顶新耀将支付700万美元（相当于约人民币4,970万元）的预付款，及不超过人民币2,400万元的自付费用报销；最高不超过8,900万美元（相当于约人民币6.32亿元）的潜在开发及销售里程碑款项；以及按净销售额的潜在特许权使用费。云顶新耀首席执行官罗永庆先生表示："我们非常高兴与Visara建立合作伙伴关系，此次战略合作引入的创新药物VIS-101兼具高度差异化与商业潜力，进一步丰富了公司的后期产品管线，并将业务拓展至眼科这一临床需求尚未充分满足且具有创新机会的蓝海治疗领域，为公司发展注入新的增长动能。未来，我们将依托公司卓越的临床开发能力和商业化平台，高效推进VIS-101这一潜在同类最佳的双功能生物制剂在中国及亚洲地区的临床开发与商业化进程，尽快为患者提供这一创新治疗选择。"VIS-101是一款新型双功能生物制剂，针对VEGF-A与ANG-2，其疗效较第一代治疗更为显著，可有望为湿性年龄相关性黄斑部病变（wet AMD）、糖尿病性黄斑部水肿（DME）及视网膜静脉阻塞（RVO）患者提供更持久的治疗效益。VIS-101已于美国及中国完成初步安全性与剂量递增研究，目前正于中国进行随机分组的剂量范围II期临床试验，预计将于2026年具备进入III期临床试验的条件。Visara联合创始人兼执行主席Cunningham博士表示："VIS-101有望成为该类别中第二款上市的药物，并具备同类最佳（best-in-class）的潜力。这源于其在生物工程上的优异设计，使其具备更强的靶点中和能力。"目前，抗VEGF（血管内皮生长因子）疗法是眼底疾病的主要治疗手段，通过抑制眼内异常新生血管的生成与渗漏，从而改善视功能。2024年全球抗VEGF眼科药物市场规模已达约230亿美元，预计到2030年将超过400亿美元。眼科药物市场空间广阔，仅在中国，wet AMD和DME的现有及新增患者人数已超过1,500万，每年新增约60万例，而目前接受抗VEGF治疗的患者人数仅约50万，存在巨大的未被满足的临床需求。Visara为新桥生物（前称为I-Mab，纳斯达克股票代码：NBP）的附属公司，云顶新耀目前是新桥生物的第一大股东。新桥生物首席执行官傅希涌博士表示："此次将VIS-101大中华区、韩国及东南亚地区的权益授权给云顶新耀，是我们在优化全球商业布局、推动全球临床开发协同方面迈出的重要一步。我们期待与云顶新耀共同推进该产品在亚洲地区的战略协作，为更多患者带来创新治疗选择。"此次合作是云顶新耀在"双轮驱动"战略指导下的又一关键落子。公司正在构建以多个大单品商业化平台为基石、以自体生成CAR-T平台与mRNA肿瘤治疗性疫苗平台的自主研发与临床转化为引擎的价值体系。未来，公司将持续聚焦优势治疗领域，引进高潜产品，进一步强化核心产品组合的协同效应。目前，云顶新耀在肾科、感染及自身免疫性疾病等核心治疗领域的产品管线已进入关键收获期。耐赋康(R)与依嘉(R)已形成可持续的商业化造血能力，维适平(R)（艾曲莫德）有望成为下一个确定性大单品。在自主研发方面，公司依托领先的mRNA肿瘤治疗性疫苗平台与自体生成CAR-T平台为核心，持续夯实自研技术壁垒。在近期的发展战略交流会上，公司进一步明确未来6-12个月计划引进3个以上的重磅产品，预计引进产品的潜在国内销售峰值将超过人民币100亿元，叠加现有产品矩阵，整体国内销售峰值有望突破人民币200亿元。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 专注于中国健康饮食行业的透云生物科技集团有限公司（「透云生物」，连同其附属公司统称「集团」；股份代号：1332.HK）欣然宣布，集团旗下全资子公司山西透云生物科技有限公司近日与中国健康产品领域知名渠道商多家核心伙伴，包括深圳楼宇间供应链科技股份有限公司、河南国字头营销管理有限公司及北京合万家生物科技有限公司，组成之销售联合体正式签署战略合作协议。根据战略合作协议，2026年至2028年底，上述销售联合体将向透云生物采购总金额不少于人民币10亿元之莱茵衣藻系列产品。此标志性合作不仅为集团莱茵衣藻业务奠定量级放大之商业基础，亦宣示相关产品线已由区域性试点阶段迈向全国化、结构化铺排与放量，进一步夯实透云生物于中国健康膳食、功能营养与绿色食品原料赛道的产业领先地位。本次采购协议的正式落地，标志着透云生物的莱茵衣藻及微藻产品已由研发验证与先导试用阶段，全面迈入可规模交付的商业化新阶段 — 即具备工业化、标准化、可持续、可追溯之稳定供应能力。是次协议属量级采购安排，亦即对产能、品质一致性、合规体系、供应链韧性及交付节奏的全方位验证。对集团而言，这不仅是一笔订单，更是一个产业拐点 — 莱茵衣藻正由「创新食材」走向「行业标配」。此里程碑进一步巩固集团「新一代绿色蛋白与功能营养供应商」之市场定位。透云生物不再只是提供单一原料，而是输出一整套可复制的营养解决方案 — 涵盖低GI配方、高蛋白/全胺基酸谱设计、富微量元素强化方案、以及针对不同消费人群（控糖人群、体重管理人群、三高风险人群、银发族等）的功能型膳食应用模组。集团预期，是次合作将在放量、场景扩展与C端渗透三个层面产生牵引效应：i) 推动其莱茵衣藻业务由区域性试点销售走向全国性铺排，实现生产端与销售端的同步扩容与规模经济；ii) 加速微藻原料进入更多日常高频品类，包括健康主食、便利即食、功能代餐、餐饮定制菜单、营养加强型小食等，使其从「创新亮点」变为「常规标配」；及iii) 以B端（餐饮、渠道、大健康企业）作为推进枢纽，带动消费端对藻基营养的认知与接受度，构建「微藻＝健康」的普遍心智，为品牌后续直接面向消费者的零售型产品铺垫基础。集团相信，随着是次协议所对应的采购需求逐步兑现，透云生物将能为健康主食、控糖控脂膳食方案、功能型即食／速食产品、代餐营养品等快速增长的细分市场，提供可持续、可标准化、可长期追溯的高规格原料底座，从而在中国「健康膳食产业升级」的进程中占据更具战略性的供应端主导位置。透云生物董事会主席兼执行董事王亮先生表示：「当前，消费者对健康饮食的理解已不再局限于传统的『少油少盐』，而是进一步聚焦于『高营养、可持续、具功能诉求』。本次签订人民币10亿元的战略采购协议，乃市场对透云生物于工业化量产能力、品质一致性、标准化交付能力以及研发迭代速度的系统性肯定。展望未来，集团将继续强化供应链韧性，在保障食品安全与品质稳定的前提下，有序扩大产能，进一步完善原料端、配方端、应用端的全链条能力。集团会持续输出标准化、模组化、低GI及富微量元素的整体营养解决方案，协助合作伙伴升级其核心产品线，并推动莱茵衣藻走入更广泛的民生场景，最终让高营养、低碳足迹的绿色食品真正普及到千家万户。透云生物的战略定位，是成为中国健康主食与功能餐饮领域的养生原料标准制定者与长期供应者，并以中国为起点，逐步走向全球。」关于透云生物科技集团有限公司透云生物科技集团有限公司（股份代号：1332.HK）主要从事莱茵衣藻产品业务、包装产品设计、研发、生产及销售业务，同时亦为向中国快速消费品提供产品包装上的二维码以及商务智慧资讯技术解决方案的市场领导者。集团扎根传统包装业务超过三十载，在香港以及广东多地设有办公室及制造车间，目前为众多世界知名品牌提供专业包装设计及制造服务，拥有长期稳定的客户群。自2020年起，集团多元化发展业务范围至莱茵衣藻、微藻产品业务，并与山西省长治市潞城区人民政府合作建设全球首座莱茵衣藻工厂，以展开莱茵衣藻工业化量产。如欲查询更多资料，请浏览集团网站：https://touyunbiotech.com.hk/zh-hant/  Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Japan – October 30, 2025 - (ACN Newswire via SeaPRwire.com) - The Northeast Asia Video Summit 2025, hosted by the Asia Video Industry Association (AVIA), brought together leading media executives, content creators, and technology innovators to explore the future of video in Japan and Korea. Held in Tokyo, the summit showcased transformative strategies in global content production, streaming monetization, and cross-border collaboration.A central theme of the summit was the global ascent of Japanese and Korean content. In a compelling keynote, Katsuaki Setoguchi, Executive Officer at TBS Holdings and President and CEO of THE SEVEN Inc., emphasized that Japan’s ambition to go global is rooted not in profit, but in cultural promotion. “Storytelling is our foundation,” Setoguchi said, highlighting the success of Alice in Borderland and upcoming co-productions with U-Next. He outlined a formula for global success: strategic IP selection, elevated production budgets, and partnerships with platforms like Netflix and Amazon to reach a global audience. Setoguchi also stressed the importance of long-term regional collaboration, particularly in Southeast Asia, citing their strategic alliance with Vietnam TV.Yu Sasamoto, CEO of DAZN Japan and APAC Business Development, shared insights into Japan’s evolving sports streaming landscape. With partnerships like Docomo and Meta, DAZN is redefining how fans engage with live sports. Sasamoto revealed that DAZN is set to triple its subscriber base in Japan and is leveraging social media to convert engagement into subscriptions. Sasamoto also shared his ambitions to expand Japanese sports globally by building an ecosystem that blends content, technology, and partnerships to scale across Asia.Streaming monetization was another hot topic. Joshua Sunghyun Cho, CBO of TVING, detailed the platform’s innovative ad strategies, including impression-guaranteed products and interactive formats like “Watch Together.” Partnering with Moloco, TVING doubled its ad revenue from KBO baseball broadcasts and is now targeting contextual and shopping ads. “Streaming is no longer just premium branding—it’s performance-driven,” Cho said. Nick Chuah, Managing Director APAC at INVIDI, added that addressable advertising is poised to reshape Japan’s TV ad market, with data-driven campaigns delivering measurable ROI and unlocking new value for brands.Executives from Dentsu, FAST Corporation, and Integral Ad Science also echoed the need for collaboration, standardization, and advocacy to accelerate CTV adoption in Japan. With new smart TVs and platforms like TVer and ABEMA entering the programmatic space, the market is poised for rapid growth.The summit also addressed the future of anime as a global cultural force. Yuichiro Saito, CEO of Studio CHIZU, and Hideki Henry Goto, President of OKUTAGON LLC, discussed anime’s expanding international footprint. With over half of revenue now coming from global markets, speakers called for new business models, international co-productions, and talent development to sustain growth, with Saito advocating for creative integrity and global collaboration.In the closing keynote, executives from Warner Bros. Discovery, SKY Perfect JSAT, and A+E Global Media debated the future of pay TV and streaming economics in Japan. While acknowledging the slow decline of linear TV, they emphasized the enduring value of local partnerships and bundling strategies. Japan’s rich history and vibrant culture continue to produce compelling stories, presenting vast opportunities for international partnerships to bring this content to global audiences. The speakers agreed that creative distribution models and co-productions will be key to unlocking Japan’s full potential on the global stage.The Northeast Asia Video Summit is proudly sponsored by Gold Sponsors Moloco and Publica by IAS, and Silver Sponsors Encompass, INVIDI and TV5MONDE.Click here for a selection of photos from the Summit.About the Asia Video Industry AssociationThe Asia Video Industry Association (AVIA) is the trade association for the video industry and ecosystem in Asia Pacific. It serves to make the video industry stronger and healthier through promoting the common interests of its members. AVIA is the interlocutor for the industry with governments across the region, leads the fight against video piracy through its Coalition Against Piracy (CAP) and provides insight into the video industry through reports and conferences aimed to support a vibrant video industry.For media enquiries and additional background information, please contact:Charmaine KwanHead of Marketing and CommunicationsEmail: charmaine@avia.org | Website: www.avia.orgLinkedIn: www.linkedin.com/company/asiavideoia |X: @AsiaVideoIA  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Placement of 20,000,000 Placement Shares at S$0.39 each has been fully taken up, raising gross proceeds of S$7.8 million.Prominent institutional funds and investors that subscribed for the Placement Shares include Lion Global Investors Limited (as investment manager for and on behalf of its clients), Asdew Acquisitions Pte Ltd, ICH Synergrowth Fund, Ginko-AGT Global Growth Fund and Mr Tan Kim Seng, among others.Supported by Singapore’s robust construction outlook of S$39 billion to S$46 billion annually from 2026 to 2029 and large-scale coastal protection initiatives of S$100 billion, the Group is well-positioned to capitalise on growth opportunities with its integrated and synergistic business model.SAC Capital Private Limited acted as the Placement Agent in relation to the Placement. Maybank Securities Pte. Ltd. acted as the Placement Agent and the Sub-Placement Agent.Singapore, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) - SGX-Catalist listed Reclaims Global Limited (“Reclaims Global” or the “Company” and together with its subsidiary, the “Group”), an eco-friendly integrated service provider within Singapore’s construction sector, is pleased to announce that the Company has successfully completed a share placement (“Placement”), comprising a total of 20,000,000 new shares issued at a price of S$0.39 per share, raising gross proceeds of S$7.8 million.With its integrated and synergistic business model within Singapore’s construction industry, the Group specialises in the customisation of excavation/demolition/building construction solutions, operating fleet management of construction vehicles and equipment as well as the recycling of construction and demolition waste.“This successful placement marks a key milestone for the Group as the macro growth momentum in Singapore’s construction industry, coupled with national investment in coastal protection initiatives, creates opportunities for Reclaims Global to deliver enhanced long-term value to our stakeholders,” said Mr. Chan Chew Leh, Executive Chairman.“Building on our established foundation and track record within the construction industry, Reclaims Global is well-positioned to pursue larger-scale projects as a trusted partner. Backed by strong sectoral tailwinds, we aim to expand our market presence and capture new business opportunities via our integrated and synergistic business model,” added Mr. Tan Kok Huat, Executive Director and Chief Executive Officer.In its latest 1H2026 results (for the financial year ended 31 July 2025) announced on 9 September 2025, Reclaims Global reported revenue growth of 14.9% to S$21.78 million (as compared to previous corresponding period) with net profit of S$2.5 million. The Company has announced an interim dividend of S$0.005 per share for 1H2026 and over the past two years, the Company has paid at least S$0.01 per share of dividends annually.About Reclaims Global Limited(SGX - NEX / Bloomberg - RGL: SP/ Reuters - RECL.SI)Listed on the Catalist of the SGX-ST in March 2019, Reclaims Global Limited is an eco-friendly integrated service provider within Singapore’s construction industry, specialising in the customisation of excavation/demolition/building construction solutions, operating fleet management of construction vehicles and equipment as well as the recycling of construction and demolition waste.The Group’s integrated and synergistic business model is organised into three main business segments as follows: (1) excavation services; (2) logistics and leasing; and (3) recycling.Since its inception in 2009, the Group has established a strong reputation and proven track record for reliable execution and timely delivery of diverse projects across the construction sector.For more information, please refer to the corporate website https://reclaims-enterprise.comIssued on behalf of Reclaims Global Limited by 8PR Asia Pte Ltd.Media & Investor Contacts:Mr. Alex TANMobile: +65 9451 5252Email: alex.tan@8prasia.com   Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 10月27日，中国新能源汽车行业中的头部企业——赛力斯集团股份有限公司（「赛力斯」，股份代号：9927）正式启动招股，赴港上市更进一步，此次上市若顺利完成，公司有望成为港股市场首家实现「A+H」两地上市的豪华新能源车企。问界M9丰富产品矩阵 市场表现亮眼作为一家以新能源汽车为核心业务的技术科技型企业，赛力斯业务版图全面覆盖新能源汽车及核心三电等产品的研发、制造、销售及服务。公司旗下高端品牌「问界」精准聚焦豪华细分市场，凭借清晰的产品定位、出色的综合性能及豪华的属性，在行业内收获高度认可，被业内人士誉为「中国的奔驰宝马」。而从科技维度出发，问界在品牌「智慧重塑豪华」理念的推动下，展现出「豪华+科技」双轨并行的独特定位。在定义未来科技出行方面，如辅助驾驶、智能安全、智能动力等，问界又与特斯拉秉持高度一致的愿景。截至目前，问界系列车型的辅助驾驶功能累计行驶里程已突破34.5亿公里，辅助驾驶行驶里程占总里程比例40%，辅助驾驶功能成绩亮眼。与此同时，赛力斯在科技创新与前沿科技持续探索，积极布局具身智能领域，近期公司已正式宣布与火山引擎达成合作，共同推进具身智能的研发与应用创新，显示出与国际领先车企不谋而合的战略前瞻性。在科技领域的成绩与探索也使得问界品牌被业内人士誉为「中国的特斯拉」。揆诸实际，无论是问界在豪华细分市场的深耕与精准定位，还是当下辅助驾驶等科技成果的稳健落地，正是对「智慧重塑豪华」品牌理念的深度践行。这一理念精准契合用户对智能与豪华并重的核心要求，让用户无需在豪华质感与智能体验间作出取舍，既避免了在单一维度发展的局限，更让「豪华 + 科技」的双重价值真正转化为用户可感知的日常使用体验。在产品端，问界品牌已构建起覆盖问界M9、问界M8、问界M7、问界M5的完整产品矩阵，实现对高端市场的全面渗透，市场表现持续亮眼，旗下主力车型长期领跑细分市场，2024年问界M9稳居50万级高端SUV销量冠军，问界M8在2025年4月正式上市后仅24小时大定即突破3万。根据Frost & Sullivan报告，问界品牌在2024年下半年以82%的NPS净推荐值登顶新能源汽车口碑榜首，且2024年问界品牌全年总交付量达38.71万辆，同比增长268%，充分印证了其在高端新能源汽车市场的核心竞争力。问界全系列强化研发投入与技术创新 业绩增长强劲在夯实产品矩阵、巩固市场份额的同时，赛力斯持续深耕技术创新领域，以高强度研发投入筑牢发展根基。于2022年、2023年、2024年以及2025年上半年，公司研发开支分别达人民币1,313.7百万元、人民币1,696.5百万元、人民币5,585.5百万元及人民币2,929.5百万元，呈现显著增长态势。从研发费用占收入比重来看，各期分别为3.9%、4.7%、3.8%及4.7%，彰显出公司对技术创新的高度重视。领先的核心技术能力，是赛力斯的产品持续实现功能创新、获得市场成功的重要驱动力之一。公司自主打造的魔方技术平台，通过平台化造车模式，有效降低了整车开发成本，同时大幅提升开发的敏捷性和灵活性。该平台凭借全景安全、多元动力、百变空间、智慧引领四大核心优势，为用户提供了「好开、好用、超安全」的智能用车体验。同时，作为首家商业化量产增程器的自主整车企业，赛力斯持续引领新能源车增程技术的发展，将增程技术从「可用」进化到「好用」，并在油电转换率和NVH性能两项关键指针上获得国家权威认证机构的认可，其最新发布的全新一代超级增程系统油电转换效率达到3.65kWh/L，处于行业量产增程器的最高水平。此外，赛力斯始终将产品安全视为底线，围绕车辆全生命周期，构建了涵盖被动安全、主动安全等九大维度的智能安全体系。目前，公司开发了81项碰撞场景，搭载该体系的问界M9荣获C-NCAP、C-IASI国内两大测评指数双第一的优异成绩。在ESG治理与可持续发展领域中，赛力斯也取得亮眼成绩，2025年10月16日，根据国际权威指数公司明晟(MSCI) 公布最新企业ESG评级结果，赛力斯集团获得最高AAA评级，成为唯一获此评级的A股上市汽车企业，彰显赛力斯集团在构建未来出行生态中的引领力量。值得一提的是，公司通过融合创新的方式与合作伙伴共同打造了先进的智能座舱和辅助驾驶功能，并通过深度融合整车控制技术，从整车跨域协同维度持续优化辅助驾驶体验，为用户提供更加智能、便捷的驾驶感受。财务表现上，赛力斯近年业绩增长势头强劲，盈利成果显著。2023年至2024年，公司收入从人民币358亿元跃升至1451亿元，同比大幅增长305.5%；公司毛利率同步提升，从2023年的7.2%稳步增至2025年上半年的26.5%，盈利空间持续拓宽。盈利层面，公司于2024年、2025年上半年分别录得归母净利润人民币59亿元、人民币29亿元，成功实现盈利突破。根据Frost & Sullivan报告，公司是全球第四家实现盈利的新能源车企，财务健康度与行业竞争力凸显。总体而言，赛力斯凭借清晰的高端产品布局、领先的技术创新与稳健的盈利增长，已在新能源汽车赛道建立起稳固的行业地位。此次拟赴港上市，既是对其过往发展成果的认可，更将为其深化技术研发、拓展全球市场注入新动能，有望在全球汽车产业变革中持续领跑，为中国自主品牌车企高质量发展写下新的注脚。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 10月27日，中国新能源汽车行业头部企业—赛力斯（股份代号：9927）启动招股，目前招股正在进行中，即将叩开港股市场大门，有望成为首家A+H豪华新能源车企。极具竞争力的产品体系在产品层面，赛力斯凭借深厚的技术积淀与精准的市场定位，构建起极具竞争力的产品体系。其中，公司于2021年重磅发布的高端品牌「问界」，截至目前，问界品牌已成功推出问界M5、问界M7、问界M8及问界M9四款核心产品，累计服务用户已突破80万。更值得关注的是，公司旗下主力车型长期稳居细分市场头部阵营，问界M9持续领跑高端SUV赛道，稳居50万级市场销量冠军。问界M8始终稳居40万级市场榜首，成为高端用户的首选之一。问界M9凭借「双旗舰」车型的亮眼表现与强大品牌影响力，赛力斯被业界高度认可，赢得了「中国的奔驰宝马」这一重磅赞誉，彰显出公司在高端新能源汽车市场的领军地位。在定义辅助驾驶、智能安全、智能动力等未来出行领域，赛力斯与特斯拉秉持高度一致的愿景。截至目前，问界系列车型的辅助驾驶功能累计行驶里程已突破34.5亿公里，在该领域，仅特斯拉与问界稳居前两位，迭加赛力斯在具身智能与科技创新领域的持续深耕与积极探索，赛力斯被行业广泛视作「中国的特斯拉」。问界对豪华市场的深耕定位与辅助驾驶等科技成果的落地，既是 “智慧重塑豪华” 理念的深度实践，也精准匹配用户对智能与豪华兼具的需求，跳出单一维度发展局限，让 “豪华 + 科技” 价值成为用户可感知的体验。全方位的技术创新实力在技术层面，赛力斯持续推动技术创新，逐步确立行业竞争优势并打造坚实的技术壁垒。公司自主研发的魔方技术平台，是具备持续进化能力的智能平台，也是行业内首个兼容增程、纯电与混动三种新能源动力总成的平台，其模块化设计使公司能够高效、可靠地实现系列车型的快速量产。目前，赛力斯最新一代超级增程系统已实现量产，热效率高达44.8%，油电转化率达到3.65kWh/L，处于行业领先水平。魔方技术平台在用户安全方面，赛力斯以全场景安全需求为驱动，全面构建覆盖被动安全、主动安全等九大维度的安全体系，涵盖超过180项用户用车场景，开发出300余项安全功能，打造全方位的安全防护能力。此外，赛力斯还构建了端云一体化的测试平台，其自研的智能测试终端可实现测试车辆7×24小时不间断的自动化测试。通过自动化测试技术，公司构建了覆盖研发、生产、供应、销售全流程的质量自动化拦截体系，全面保障产品质量。赛力斯在 ESG 治理与可持续发展领域同样成效显著，2025 年 10 月 16 日拿下国际权威机构明晟（MSCI）最高 AAA 评级，作为 A 股上市车企中唯一获此评级的企业，其未来出行生态引领地位得以凸显。财务方面，赛力斯近年来实现跨越式增长，业绩表现尤为亮眼。2024年营业收入突破1451亿元，同比增长305.5%，实现归母净利润59亿元，成功实现历史性扭亏为盈，2025年上半年，公司延续盈利向好态势，实现净利润29亿元，展现出强劲增长势头。赛力斯以产品力、技术壁垒与安全体系筑牢发展根基，凭亮眼财务数据印证强劲实力。若此次赴港上市顺利落地，其将正式开启「A+H」双资本平台驱动模式，未来有望持续领跑高端新能源赛道，书写行业发展新篇章。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亚太商訊) - 汽车产业迈向电动化、智能化转型的关键时刻，中国品牌正加速崛起。赛力斯集团股份有限公司（下称「赛力斯」，股份代号：9927）于10月27日正式开启港股招股，有望成为首家实现A+H两地上市的豪华新能源汽车企业。此次IPO，赛力斯计划全球发售100,200,000股股份，最高发售价为每股131.50港元，预计募集资金净额约129.249亿港元，并定于11月5日正式登陆香港联合交易所。此次上市由中金公司与中国银河国际担任联席保荐人。赛力斯旗下高端品牌「问界」（AITO）凭借其系列车型，已在30万元至50万元级别的细分市场中领跑，被业界誉为「中国的Mercedes Benz宝马」。问界以「智慧重塑豪华」为核心理念，不仅契合用户对智能科技与豪华驾乘的双重追求，同时也因其在辅助驾驶、智能安全及智能动力等方面的技术成果，被视为「中国的特斯拉」，展现出与全球顶尖智能电动车制造商一致的愿景。技术积淀与华为深度合作赛力斯的成功并非偶然，其背后是超过三十年的技术积淀。公司自1986年创立以来，深耕汽车制造领域，从传统燃油车的扎实制造基础，平稳过渡至新能源汽车的创新浪潮。2021年，问界品牌的发布标志着赛力斯正式锚定豪华新能源汽车赛道，并确立了「用户定义汽车」的市场导向与「软件定义汽车」的技术路线，迅速构筑起差异化的竞争优势。问界目前已形成M5、M7、M8、M9四大主力产品矩阵，通过精准的价格梯度与场景化功能组合，全面抢占高端用户市场。问界系列车型亦受益于与华为的深度合作，而华为作为智能汽车系统的领军者，为问界提供了强大的智能驾驶和智能座舱技术支持，使其在辅助驾驶的体验和智能化水平上，持续保持行业领先地位，这也是问界系列能够获得市场认可的关键要素。问界M9领跑高端市场问界品牌的强劲表现已在销售数据上得到充分印证。2024年，问界全年交付量达到38.71万辆，同比实现268%的爆炸性增长。在细分市场中，旗舰车型问界M9上市仅10个月内生产逾15万辆，一举拿下50万元级别的销量冠军宝座，展现出强大的品牌力和市场号召力。为保障产品质量与交付效率，赛力斯投入巨资建设「超级工厂」并优化数字化供应链体系，有力支撑了产品「上市即上量」的策略。在实现垂直上量交付的同时，问界M9系列在垂直上量交付中至今未出现任何重大质量问题，为业界树立了高质量交付的新标杆。赛力斯此次赴港上市，不仅是其发展历程中的重要里程碑，更将为国际投资者提供一个深度参与中国豪华智能电动车市场高速增长的绝佳机会。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) - OTS Holdings Limited (“OTS Holdings” or the “Company”, and together with its subsidiaries, the “Group”), a brand builder and food manufacturing group, is pleased to announce the grand opening of its new advanced food manufacturing facility located at Lot 1734, Jalan Kampung Pisang, Bukit Keremoiyang, 86200 Simpang Renggam, Johor Darul Takzim, Malaysia. The facility will operate under a wholly-owned subsidiary Ellaziq (Malaysia) Sdn. Bhd.The event on 28 October 2025 was graced by Yang Berhormat Tuan Lee Ting Han, Chairman of the Johor State Investment, Trade, Consumer Affairs and Human Resources Committee, along with representatives from the Malaysian Investment Development Authority (MIDA), Enterprise Singapore, the Singapore Business Federation, the Johor State Islamic Religious Department, as well as representatives from banking institutions, partners, and business associates.From left to right: 1. Mr. Mohamad Reduan Mohd Zabri, Director, MIDA Johor; 2. Ms. Wan Hariati Wan Salleh, Senior Deputy Director, Food Technology & Resources Based Industries Division, MIDA; 3. Yang Berhormat Tuan Lee Ting Han, Chairman of Johor State Investment, Trade, Consumer Affairs and Human Resources Committee; 4. Mr. Ong Bee Chip, Managing Director, OTS Holdings Limited; 5. Mdm. Ong Chew Yong, Executive Director, OTS Holdings Limited; and 6. Dr. Yu Lai Boon, Non-Executive Chairman and Independent Director, OTS Holdings LimitedWith a total investment of approximately RM40 million, the new Johor manufacturing facility is halal certified and equipped with new advanced F&B machinery and automation, boosting the Group’s monthly halal production capacity by up to 200 tonnes — more than three times of its Singapore’s halal production output.Backed by advanced production capabilities and in-house R&D expertise, the Group has undertaken extensive renovation and upgrading works, since acquiring the property for RM14.3 million in November 2023, to ensure the new facility aligns with the Group’s stringent food manufacturing standards, quality controls and operational requirements.With a land size of 178,863 square feet, the Johor manufacturing facility has a built-up area of 65,000 square feet that includes office space, production and maintenance facility with boilerhouse and workshop.Dedicated exclusively to halal production, the Johor manufacturing facility has successfully obtained its halal certification in August 2025.Notably, the Johor manufacturing facility is equipped with new advanced F&B machinery and automation, which will enable the Group to maintain stringent quality standards while operating with a lean workforce.In comparison to the Singapore facility, which produces 60 tonnes of halal products monthly within 17,000 square feet, the Johor plant will boast a capacity of up to 200 tonnes per month — more than three times of Singapore’s production output.Commenting on the grand opening of its new Johor manufacturing facility, Managing Director of OTS Holdings, Mr. Ong Bee Chip said: “Our new Johor facility reflects our commitment to meeting the evolving needs of the Muslim consumer segment, which continues to grow both in value and demand.Our focus is not just on increasing volume, but on creating products that resonate with the values and expectations of the Muslim community, while maintaining the stringent standards of food quality and safety.Targeting the growing Muslim consumer market locally and abroad—from Singapore and Malaysia to the Middle East, UAE, and Africa, our enhanced production capacity will also strengthen our export capabilities, extending our trusted halal brands and high quality products to a larger audience globally.”About OTS Holdings Limited(Bloomberg: OTS:SP / SGX Stock Code: OTS)Established in 1993, OTS Holdings Limited is a brand builder and food manufacturing group in the consumer industry with a strong niche in ready-to-eat and ready-to-cook meat products with key markets in Singapore and Malaysia.The Group’s vision is to develop a growing portfolio of established consumer brands and become an innovative market leader in the region. Targeting both halal and non-halal consumer segments, the Group has more than 1,100 SKUs across 13 main product types under its eight house brands and notably the Group’s flagship brands, “Golden Bridge” and “Kelly’s” have become established household names within the ready-to-eat and ready-to-cook meat products market in Singapore and Malaysia.The Group owns and operates three modern food manufacturing facilities, two in Singapore and one in Simpang Renggam, Johor, Malaysia. In Singapore, its integrated food manufacturing facilities with in-house research and development team span across around 98,285 square feet with an average annual production of around 2,500 tonnes of ready-to-eat and ready-to-cook meat products.The Group’s food products are sold in major supermarkets, convenience stores, provision shops, hotels and restaurants in Singapore and Malaysia. Having built an established sales and distribution network over the past few decades, the Group aims to expand its presence in existing markets and overseas.For more information, please visit the Company’s website at www.ots-holdings.com.Issued on behalf of OTS Holdings Limited by 8PR Asia Pte Ltd.Media & Investor Contacts:Mr. Alex TANMobile: +65 9451 5252Email: alex.tan@8prasia.com  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

LONDON, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) - New research from the Institute for Economics & Peace reveals that changing rainfall patterns are significantly amplifying conflict risks worldwide. The 2025 Ecological Threat Report (ETR), released today, finds conflict death rates are substantially higher in areas where rainfall is concentrating into fewer months, compared to regions where rain is spreading more evenly throughout the year.Ecological Threat Report 2025Analysing Ecological Threats, Resilience & PeaceKey FindingsOn average in areas where wet and dry seasons are becoming more extreme, there are four times as many conflict deaths as areas where it has decreased.In 2024, natural hazards triggered 45 million short-term internal displacements across 163 countries, the highest figure since at least 2008.Western Brazil, including parts of the Amazon, has recorded some of the world's sharpest increases in ecological threat levels. Temperatures have risen at twice the global rate, triggering drought and wildfires.Sub-Saharan Africa faces the world's most severe ecological pressures, with Niger registering the worst ETR score.Central and Western Europe recorded substantial overall improvements, in part representing a return to normalcy following Europe's unusually dry climatic conditions in 2019.Despite fears of looming water wars, there have been no interstate conflicts fought exclusively over water in the modern era. In the second half of the 20th century, at least 157 international freshwater treaties have been signed, offering models for interstate cooperation.This cooperative approach to water somewhat mirrors nuclear deterrence since the Second World War. In both cases, the very threat of catastrophic destruction has created pragmatic cooperation. The destruction of water supply can lead to societal collapse.Approximately 2 billion people - one quarter of humanity - now live in regions experiencing moderate to severe increases in seasonality. This is where wet seasons are becoming shorter and more intense, while dry seasons are longer and drier. These changes are disrupting agricultural calendars and heightening uncertainty for billions of people who rely on seasonal rains for food and livelihoods.The Ecological Threat Report, produced by the Institute for Economics & Peace, covers 3,125 sub-national areas in 172 countries and territories representing more than 99% of the world's population. Between 2019 and 2024, ETR scores deteriorated in 96 countries and improved in 74.Sub-Saharan Africa Approaching Multiple Critical Tipping PointsIn sub-Saharan Africa, conflict risk rises sharply when seasonality combines with rapid population growth. Unpredictable rains trigger agricultural stress. When coupled with demographic pressure, competition over land, water and food intensifies. In regions with weak governance and unresolved grievances, this combination proves combustible.The Karamoja Cluster in East Africa illustrates this pattern. While total rainfall remains relatively stable, its timing has become less predictable, amplifying both drought and flood hazards, leading to increased conflict. With only 2% of cultivated land irrigated compared to a global average of 20%, East African communities remain highly vulnerable to these shocks. Since 2019, increased rainfall seasonality has coincided with a resurgence of pastoralist violence after years of relative peace."Rainfall seasonality is becoming a powerful conflict catalyst,"said Steve Killelea AM, Founder & Executive Chairman of the Institute for Economics & Peace."Where rains are increasingly concentrated into fewer months, conflict deaths rise sharply. In sub-Saharan Africa, rapid population growth amplifies this effect, turning unpredictable seasons into competition for land, water and food. The issue isn't water scarcity - it's our failure to capture and distribute it. Only 2% of Sub-Saharan African farmland is irrigated, compared to 20% globally."Water Inequality and the Infrastructure GapThe world's renewable freshwater supply is finite and increasingly unevenly distributed. There are 295 subnational areas facing very high water risk and another 780 with high risk, affecting nearly 1.9 billion people.High-income countries have reduced per capita water use by roughly one-third since 2000 through efficiency gains and slower population growth, while many low-income nations face rising total withdrawals and falling per capita availability as populations outpace supply.Sub-Saharan Africa highlights this imbalance. Per capita water use has dropped from 113 cubic metres in 2000 to just 89 in 2022 - less than one-fifth of the global average. The result is mounting pressure on limited water sources and intensifying competition among farms, industries and households, heightening the risk of conflict.The failure to capture and distribute water is most acute in sub-Saharan Africa, which has the lowest irrigation rates in the world. To irrigate 34 million hectares would require only 6% of the region's annual renewable water resources.Steve Killelea said: "COP30 must prioritise investment in climate-resilient water systems as a foundation for sustainability and peace. Just as nuclear treaties reduced the risk of annihilation, international cooperation on water can reduce the risk of ecological collapse. Both demonstrate that survival depends less on dominance, than on shared responsibility."Interstate Water CooperationPopular narratives have warned of looming "water wars", especially in transboundary river and lake basins. The ETR finds this is not the case. While disputes over shared rivers do occur, no interstate wars have been fought over water in the modern era. This makes the lessons of successful interstate water cooperation even more important. In an era of increasing conflict, understanding why interstate cooperation has been so successful can provide a blueprint for avoiding future conflicts.Even in tense basins such as the Indus River - shared by India and Pakistan - water-sharing has continued despite repeated episodes of conflict, political confrontations and military tension. Water agreements, by necessity, encourage nations to think beyond immediate political grievances toward long-term survival and shared benefit.Regional AnalysisSub-Saharan Africa faces the world's most severe ecological pressures. However, some southern and eastern African countries, including Lesotho, Rwanda, Eritrea and Eswatini, have improved their ETR scores. More favourable rainfall patterns in these countries resulted in marked reductions in water risk over the past five years.In contrast, northwest Africa has seen the steepest deterioration in ETR scores over the same period, led by Tunisia, Morocco and Algeria, where persistent drought and rising temperatures have reversed the unusually favourable conditions of 2019.Central and Western Europe recorded notable improvements, marking a return to normal following the extreme dryness of 2019.Contact InformationMike KoslowskiIEP Senior Communications Advisormkoslowski@economicsandpeace.org+61418410531SOURCE: Institute for Economics & PeaceRelated Images Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com